rs368392588
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_003476.5(CSRP3):c.190C>T(p.Arg64Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000459 in 1,613,528 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R64H) has been classified as Uncertain significance.
Frequency
Consequence
NM_003476.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CSRP3 | NM_003476.5 | c.190C>T | p.Arg64Cys | missense_variant | 3/6 | ENST00000265968.9 | |
CSRP3 | NM_001369404.1 | c.113-1879C>T | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CSRP3 | ENST00000265968.9 | c.190C>T | p.Arg64Cys | missense_variant | 3/6 | 1 | NM_003476.5 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000855 AC: 13AN: 152120Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251244Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135786
GnomAD4 exome AF: 0.0000417 AC: 61AN: 1461290Hom.: 1 Cov.: 32 AF XY: 0.0000413 AC XY: 30AN XY: 726948
GnomAD4 genome ? AF: 0.0000854 AC: 13AN: 152238Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74424
ClinVar
Submissions by phenotype
Dilated cardiomyopathy 1M;C2677491:Hypertrophic cardiomyopathy 12 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 09, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Invitae | Jan 14, 2024 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 64 of the CSRP3 protein (p.Arg64Cys). This variant is present in population databases (rs368392588, gnomAD 0.01%). This missense change has been observed in individuals with clinical features of CSRP3-related conditions and/or hypertrophic cardiomyopathy (PMID: 16352453; Invitae). ClinVar contains an entry for this variant (Variation ID: 520355). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Mar 05, 2019 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 18, 2021 | Identified in patients with HCM in the published literature (Bos et al., 2006; Janin et al., 2018); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Reported in ClinVar as a variant of uncertain significance (ClinVar Variant ID# 520355; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 23299917, 30012424, 16352453) - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 02, 2022 | The p.R64C variant (also known as c.190C>T), located in coding exon 2 of the CSRP3 gene, results from a C to T substitution at nucleotide position 190. The arginine at codon 64 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration has been reported in an individual with hypertrophic cardiomyopathy (Bos JM et al. Mol. Genet. Metab., 2006 May;88:78-85). This variant has also been seen in exome cohorts not selected for the presence of cardiovascular disease, but clinical details were limited (Andreasen C et al. Eur. J. Hum. Genet., 2013 Sep;21:918-28; Kars ME et al. Proc Natl Acad Sci U S A. 2021 09;118(36)). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Hypertrophic cardiomyopathy 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Apr 10, 2019 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at